miR-21-3p antagomiR

miR-21-3p antagomiR is a chemically modified antisense oligonucleotide designed to specifically bind to and inhibit the activity of microRNA-21-3p (miR-21-3p), a small non-coding RNA molecule involved in the regulation of gene expression[8]. Inhibition of miR-21-3p has been shown to have protective effects in the heart by altering macrophage polarization (reducing pro-inflammatory M1 phenotype), decreasing excessive mitophagy, and upregulating the mitochondrial fatty acid oxidation enzyme CPT1A, which is crucial for cardiac energy metabolism[1]. This intervention can mitigate myocardial fibrosis, improve cardiac function, and reduce markers of cardiac injury in experimental models of chronic heart failure and sepsis-induced cardiac dysfunction[1]. miR-21-3p antagomiR has also been investigated in other contexts, including wound healing and fibrotic diseases, where modulation of miR-21-3p levels affects fibroblast proliferation and collagen synthesis[3]. While promising in preclinical studies, miR-21-3p antagomiR is not an approved therapy and remains primarily a research tool.

Other names

miR-21-3p inhibitormiR21-3p inhibitormiR 21-3p inhibitorantagomiR-21-3pantagomiR21-3pantagomiR 21-3p